(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model
Multispecific CD73/PD-1 targeting
Abstract
The approval of PD-(L)1 axis inhibitors have firmly established immunotherapy as an effective cancer treatment option with reduced adverse effects compared with conventional chemotherapy1. However, while anti-PD-(L)1 therapy has demonstrated durable responses, only a small subset of patients respond. One mechanism of tumor escape from anti-PD-1 therapy is via the release of immunosuppressive metabolites such as adenosine. CD73, an extracellular enzyme expressed on immune cells and some tumors, catalyzes the rate limiting step in adenosine production, the conversion of AMP to adenosine2(Figure 1A/B). As a strategy to improve response rates, we developed a first-in class multispecific CD73/PD-1 targeting DFC. Herein, we describe CD73/PD-1-001, a dual targeting DFC comprising a multivalent conjugate of a small molecule CD73 inhibitor stably linked to a proprietary human IgG1 Fc-fusion with a PD-1 inhibitor peptide (Figure 2). This multispecific DFC has the potential for differentiation and increased therapeutic efficacy compared to approved PD-(L)1 inhibitors.
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667bc72bd3a4f7cf5ac84f05_cidara_poster_AACR2024_PD-1-PD-L1_website_img01.webp)
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667bc738fb5c9c9a7a64596f_cidara_poster_AACR2024_PD-1-PD-L1_website_img02.webp)
Related products
Catalogue product
Customized product
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate